-
Mashup Score: 0The Success of Your Tech Deployment Depends On A Role You’ve Probably Never Heard Of - TimmermanReport.com - 1 year(s) ago
The success or failure of many technology platforms — including in particular health tech platforms — rests with a largely obscure role of outsized importance: the “solutions engineer.” The role itself goes by many names. Back when I was at DNAnexus in the mid-2010s, this role was called “Solutions Scientist.” Others call it “Forward-Deployed Engineer”… Read More
Source: Timmerman ReportCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1The Success of Your Tech Deployment Depends On A Role You’ve Probably Never Heard Of - TimmermanReport.com - 1 year(s) ago
The success or failure of many technology platforms — including in particular health tech platforms — rests with a largely obscure role of outsized importance: the “solutions engineer.” The role itself goes by many names. Back when I was at DNAnexus in the mid-2010s, this role was called “Solutions Scientist.” Others call it “Forward-Deployed Engineer”… Read More
Source: Timmerman ReportCategories: Hem/Oncs, Latest HeadlinesTweet-
Today in @timmermanreport, @DShaywitz writes about what's needed to successfully deploy new technologies and data, and how solutions engineers serve as critical translators. It was great to share perspective for this story: https://t.co/sDyPn9uo2O
-
-
Mashup Score: 2
Companies at the frontiers of science and medicine, developing new therapies for patients, are working on one of the most challenging endeavors known to humanity. Most would agree it’s more difficult than putting a man on the moon. The pandemic created a dramatic disruption to our globally networked economy. It will have far-ranging and long-lasting… Read More
Source: Timmerman ReportCategories: Cardiologists, Latest HeadlinesTweet-
Nice read @JMaraganore https://t.co/Eimi6rODtV
-
-
Mashup Score: 0Kilimanjaro 2023 - TimmermanReport.com - 1 year(s) ago
Is the Climb to Fight Cancer/Fred Hutchinson Cancer Center a 501(c)(3) nonprofit institution and is my donation tax-deductible? Yes. Climb to Fight Cancer is an event put on by Fred Hutch, a nonprofit organization incorporated in the state of Washington, that accepts donations from all 50 states. Our tax ID number is 23-7156071. All donations are tax-deductible to the extent allowed by law. The…
Source: Timmerman ReportCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Great to see @ldtimmerman and company prep for their upcoming expedition to the summit of Mt. Kilimanjaro! The team is also raising funds to support lifesaving research at Fred Hutch. Learn more: https://t.co/4zBCyNPjJ4 https://t.co/q8Jm0JoUbA
-
-
Mashup Score: 0You Have Chosen … Poorly: Why Drug Developers Make Bad Decisions - TimmermanReport.com - 2 year(s) ago
Drug development remains an incredibly expensive endeavor. Much of the cost can be attributed to late-stage clinical trial failures. The burden is borne first and foremost by clinical trial participants who aren’t helped by the experimental medicine. It also significantly impacts the companies sponsoring these studies. Everyone would like to improve the chances that a… Read More
Source: Timmerman ReportCategories: Hem/Oncs, Latest HeadlinesTweet-
You have chosen ... poorly! Why drug developers make bad decisions https://t.co/ZWRYiXwL5X via @DShaywitz
-
-
Mashup Score: 2
Living in innovative domains like biomedical research requires an appreciation for the exceptional, the outlier. You might even argue that the goal of innovators – at least those who hope to see their ideas gain acceptance, or their inventions adopted – is to institutionalize the exceptional and make it routine. In the Perez model of… Read More
Source: Timmerman ReportCategories: Hem/Oncs, Latest HeadlinesTweet-
Insightful and inspiring piece by @DShaywitz in today's @timmermanreport. He speaks to the importance of embracing the exceptional — something we must "celebrate, nurture, and relentlessly pursue": https://t.co/lkvCqkv9xy
-
-
Mashup Score: 1An Open Letter from Female Biotech Leaders on Post-Roe America - TimmermanReport.com - 2 year(s) ago
[Editor’s Note: this letter was drafted by female biotech leaders in response to the Supreme Court’s Dobbs decision. It was co-signed by more than 65 female biotech executives as of July 1. They’re listed at the end.] Friends and colleagues, legislators and elected officials We join the resounding millions in chorus to express our profound… Read More
Source: Timmerman ReportCategories: Future of Medicine, Latest HeadlinesTweet-
"We join the resounding millions in chorus to express our profound dismay and disappointment at the US Supreme Court’s decision": An open letter from female biotech leaders on post-Roe America #NBTNewsBeat https://t.co/FVIP3M22sB
-
-
Mashup Score: 6The Limits of Biomedical Innovation, and Why We Should Embrace Them - TimmermanReport.com - 2 year(s) ago
Last October, I wrote for this publication about the emergence of Antibody-Drug Conjugates (ADCs) for cancer, based on my father’s experience being treated with Padcev for bladder cancer. A few months later, I posted on Twitter that, while Padcev had stopped working for my father, he had since started on another ADC called Trodelvy. His… Read More
Source: Timmerman ReportCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DShaywitz: Powerful, poignant, sad, and beautiful by @AlexHarding7 in @timmermanreport https://t.co/fMERkxLTuW
-
-
Mashup Score: 0The Limits of Biomedical Innovation, and Why We Should Embrace Them - TimmermanReport.com - 2 year(s) ago
Last October, I wrote for this publication about the emergence of Antibody-Drug Conjugates (ADCs) for cancer, based on my father’s experience being treated with Padcev for bladder cancer. A few months later, I posted on Twitter that, while Padcev had stopped working for my father, he had since started on another ADC called Trodelvy. His… Read More
Source: Timmerman ReportCategories: Healthcare Professionals, Latest HeadlinesTweet-
Powerful, poignant, sad, and beautiful by @AlexHarding7 in @timmermanreport https://t.co/fMERkxLTuW
-
-
Mashup Score: 4An Old Idea Whose Time Has Come - TimmermanReport.com - 2 year(s) ago
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Source: Timmerman ReportCategories: Latest Headlines, Oncologists1Tweet-
In today's @timmermanreport, @ldtimmerman explores the walking meeting, one of my favorite ways to get work done. I shared some thoughts and tips with him (watch your step!), along with fellow walkers and talkers @DShaywitz, Mostafa Ronaghi: https://t.co/aZW1WACnKX
-
The Success of Your Tech Deployment Depends On A Role You’ve Probably Never Heard Of - Hmm do we have many of these in the nhs ? What do we call them ? @tara_donnelly1 https://t.co/6HiL044TGQ